Fulminant chemical hepatitis possibly associated with donepezil and sertraline therapy

Journal of the American Geriatrics Society

Volumn 48, Issue 12, 2000, Pages 1659-1663

  Verrico, Margaret M ^a,b   Nace, David A ^a,c   Towers, Adele L ^a,c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Universigy of Pittsburgh   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Alzheimer's disease; donepezil; hepatotoxicity; Selective Serotonin Re uptake Inhibitors; sertraline

Indexed keywords

ALKALINE PHOSPHATASE; BILIRUBIN; DONEPEZIL; GAMMA GLUTAMYLTRANSFERASE; INDAN DERIVATIVE; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

AGED; ALZHEIMER DISEASE; ARTICLE; BIOPSY; BLOOD; CASE REPORT; CHEMICALLY INDUCED DISORDER; CHOLESTASIS; COMPUTER ASSISTED TOMOGRAPHY; DRUG COMBINATION; DRUG MONITORING; FEMALE; HUMAN; LIVER FAILURE; LIVER FUNCTION TEST; TOXIC HEPATITIS;

AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; ALZHEIMER DISEASE; BILIRUBIN; BIOPSY; CHOLESTASIS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS, TOXIC; HUMANS; INDANS; LIVER FAILURE, ACUTE; LIVER FUNCTION TESTS; NOOTROPIC AGENTS; PIPERIDINES; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0034543763     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2000.tb03879.x     Document Type: Article

References (43)

1. Rogers SL, Friedhoff LT, Apter JT, et al,. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7: 293-303.
2. Rogers SL, Doody RS, Mohs RC, et al,. Donepezil improves cognition and global function in Alzheimer disease. Arch Intern Med 1998; 158: 1021-1031.
3. Rogers SL, Farlow MR, Doody RS, et al,. A 24-week, double blind, placebocontrolled trial of donepezil in patients with Alzheimer's disease. Neurology. 1998; 50: 136-145.
4. Eisia Co. Aricept™ (donepezil hydrochloride) product information. Teaneck, NJ, December 1996.
5. Shintani E, Uchida KM,. Donepezil: An anticholinesterase inhibitor for Alzheimer's disease. Am J Health-Syst Pharm 1997; 54: 2805-2810.
6. Watkins PB, Zimmerman, H, Knapp MJ, et al,. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271: 992-998.
7. Warner Lambert Company. Cognex® (tacrine hydrochloride) product information. Morris Plains, NJ, 1993.
8. O'Brien JT, Eagger S, Levy R,. Effects of tetrahydroaminoacridine on liver function in patients with Alzheimer's disease. Age Aging 1991; 20: 129-131.
9. Zemlan FP, Keys M, Richter RW, Strub RL,. Double-blind, placebo-controlled study of velnacrine in Alzheimer's disease. Life Sci 1996; 58: 1823-1832.
10. Blackard WG, Sood GK, Crowe DR, Fallon MB,. Tacrine: A cause of fatal hepatotoxicity? J Clin Gastroenterol 1998; 26: 57-59.
11. Hammel P, Larrey D, Bernau J, Kalafat M, et al,. Acute hepatitis after tetrahydroaminoacridine administration for Alzheimer's disease. J Clin Gastroenterol 1990; 12: 329-31.
12. Chattelier G, Lacomblez L,. Tacrine (tetrahydroaminoacridine) and lecithin in senile dementia of the Alzheimer's type: A multicenter trial. BMJ 1990; 300: 495-499.
13. Madden S, Woolf TF, Pool WF, Park BK,. An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro studies with human and liver microsomes. Biochem Pharmacol 1993; 46: 13-20.
14. Fontana RJ, Durkeon DK, Woolf TF, et al,. The caffeine test does not identify patients susceptible to tacrine hepatotoxicity. Hepatology 1996; 23: 1429-1435.
15. Park BK, Madden S, Spaldin V, et al,. Tacrine transaminitis: Potential mechanisms. Alzheimer's Dis Assoc Disord 1994; 8: S39-49.
16. Roerig Division of Pfizer, Inc. Zoloft® (sertraline hydrochloride) package insert. New York, NY, October 1997.
17. Wernicke JF,. The side effect profile and the safety of fluoxetine. J Clin Psychiatry 1985; 46 (3 Part 2): 59-67.
18. Castiella A, Arenas JI,. Fluoxetine hepatotoxicity (letter). Am J Gastroenterol 1994; 89: 458-459.
19. Friedenberg FK, Rothstein KD,. Hepatitis secondary to fluoxetine treatment (letter). Am J Psychiatry 1996; 153: 580-1.
20. Johnston DE, Wheeler DE,. Chronic hepatitis related to the use of fluoxetine. Am J Gastroenterol 1997; 92: 1225-1226.
21. Green BH,. Fluvoxamine and hepatic function (letter). Br J Psychiatry 1988; 153: 130-131.
22. Smith Kline Beecham Pharmaceuticals. Paxil (paroxetine) package insert. Philadelphia, PA, December 1992.
23. Helmchen C, Boerner RJ, Meyendorf R, Hegerl U,. Reversible hepatotoxicity of paroxetine in a patient with major depression. Pharmacopsychiatry 1996; 29: 223-226.
24. Benbow SJ, Gill G,. Drug points: Paroxetine and hepatotoxicity. BMJ 1997; 314: 1387.
25. Kuhs H, Rudolf GAE,. A double-blind study of the comparative antidepressant effect of paroxetine and amitriptyline. Acta Psychiatr Scand 1989; 80 (Suppl 350): 145-146.
26. Hoechst Marion Roussel, Inc. Cardizem CD (diltiazem hydrochloride) product information. Kansas City, MO, December 1995.
27. Pool PE, Massie BM, Venkataraman K, et al,. Diltiazem as monotherapy for systemic hypertension: A multicenter, randomized, placebo-controlled trial. Am J Cardiol 1986; 57: 212-217.
28. Traverse JH, Swenson LJ, McBride KW,. Acute hepatic injury after treatment with diltiazem. Am Heart J 1994; 127: 1636-1639.
29. Sarachek NS, London RL, Matulewicz TJ,. Diltiazem and granulomatous hepatitis. Gastroenterology 1985; 88: 1260-1262.
30. Shallcross H, Padley SPG, Glynn MJ, Gibbs DD,. Fatal renal and hepatic toxicity after treatment with diltiazem. BMJ 1987; 295: 1236-1237.
31. Lavrijsen AP, Van Dijke C, Vermeer BJ,. Diltiazem-associated exfoliative dermatitis in a patient with psoriasis. Acta Derm Venereol 1986; 66: 536-538.
32. Avila JR,. Elevation of hepatic enzymes after cutaneous reaction caused by diltiazem. Ann Pharmacother 1995; 29: 317-318.
33. Brodsky SJ, Cutler SS, Weiner DA, et al,. Hepatotoxicity due to treatment with verapamil. Ann Intern Med 1981; 94: 490-491.
34. Nash DT, Peer TD,. Hepatic injury possibly induced by verapamil. JAMA 1983; 249: 396.
35. Abramson M, Littlejohn GO,. Hepatic reactions to nifedipine. Med J Aust 1985; 142: 47-48.
36. Evans WE, Self TH, Weisburst MR,. Phenobarbital-induced hepatic dysfunction. Drug Intell Clin Pharm 1976; 10: 439-443.
37. Kahn HD, Faquet GB, Agee JF, et al,. Drug-induced liver injury. Arch Intern Med 1984; 144: 1677-1679.
38. Weisburst M, Self T, Peace R, Cooper J,. Jaundice and rash associated with the use of phenobarbital and hydrochlorothiazide. South Med J 1976; 69: 126.
39. Handfield-Jones SE, Jenkins RE, Whittaker SJ, et al,. The anticonvulsant hypersensitivity syndrome. Br J Dermatol 1993; 129: 175-177.
40. Vittoria CC, Muglia JJ,. Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995; 155: 2285-2290.
41. Mullen WJ, North DS, Weiss MA,. Pharm Pract News 1998; 3: 21-24.
42. Richelson E,. Pharmacokinetic drug interactions of new antidepressants: A review of the effects of metabolism of other drugs. Mayo Clin Proc 1997; 72: 835-847.
43. Cadranel JF, Di Martino V, Cazier A, et al,. Atrium and paroxetine related severe hepatitis. J Clin Gastroenterol 1999; 28: 52-55.